Suresh C. Srivastava
(Medical Department, Brookhaven National Laboratory, Upton, New York 11973, U.S.A.)
22/09/2011, 16:30
Radiopharmaceuticals Chemistry
oral presentation
This presentation will introduce a relatively novel paradigm that involves specific individual radionuclides or radionuclide pairs that have emissions that allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may potentially bring us closer to the...
Prof.
Aleksander Bilewicz
(Institute of Nuclear Chemistry and Technology)
22/09/2011, 16:50
Radiopharmaceuticals Chemistry
oral presentation
Objectives: Two isotopes of scandium, 47Sc and 44Sc, are perspective radionuclides respectively for radiotherapy and diagnostic imaging. 47Sc decays with the half-life of 3.35 days and maximum β- energy of 600 keV. It also emits low-energy γ-radiation (Eγ = 159 keV) suitable for simultaneous imaging. The other scandium radionuclide, 44Sc (t1/2 = 3.92h) is an ideal β+-emitter in PET diagnosis....
Prof.
Alessandro Dolmella
(University of Padova, Italy)
22/09/2011, 17:05
Radiopharmaceuticals Chemistry
oral presentation
99mTc(N)-DBODC(5) is a lipophilic cationic mixed-compound currently under clinical investigation as potential myocardial imaging agent. The findings that this complex accumulates in mitochondrial structures through a mechanism mediated by the negative mitochondrial membrane potential, and that the rapid efflux of 99mTc(N)-DBODC(5) from non-target tissues seems correlated to the Pgp/MDR-Pgp...
